{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:46:16Z","timestamp":1756896376327},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The mechanisms underlying the therapeutic activity of interferon-\u03b2 in multiple sclerosis are still not completely understood. In the present study, we evaluated the short and long-term effects of interferon-\u03b2 treatment on different subsets of regulatory T cells in relapsing\u2013remitting multiple sclerosis patients biologically responsive to treatment because of mixovirus resistance\u00a0protein A inducibility.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>In this prospective longitudinal study, subsets of natural regulatory T cells (na\u00efve, central memory and effector memory) and inducible regulatory T cells (Tr1), as well as in vitro-induced regulatory T cells (Tr1-like cells), were simultaneously quantified by flow cytometry in samples prepared from 148 therapy-na\u00efve multiple sclerosis patients obtained before and after 6, 12, 18, and 24\u00a0months of interferon-\u03b2-1a treatment. mRNA for interleukin-10 and Tr1-related genes (CD18, CD49b, and CD46, together with Cyt-1 and Cyt-2 CD46-associated isoforms) were quantified in Tr1-like cells.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Despite profound inter-individual variations in the modulation of all regulatory T-cell subsets, the percentage of natural regulatory T cells increased after 6, 12, and 24\u00a0months of interferon-\u03b2 treatment. This increase was characterized by the expansion of central and effector memory regulatory T-cell subsets. The percentage of Tr1 significantly enhanced at 12\u00a0months of therapy and continued to be high at the subsequent evaluation points. Patients experiencing relapses displayed a higher percentage of na\u00efve regulatory T cells and a lower percentage of central memory regulatory T cells and of Tr1 before starting interferon-\u03b2 therapy. In addition, an increase over time of central memory and of Tr1 was observed only in patients with stable disease. However, in vitro-induced Tr1-like cells, prepared from patients treated for 24\u00a0months, produced less amount of interleukin-10 mRNA compared with pre-treatment Tr1-like cells.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Interferon-\u03b2 induces the expansion of T regulatory subsets endowed with a high suppressive activity, especially in clinically stable patients. The overall concurrent modulation of natural and inducible regulatory T-cell subsets might explain the therapeutic effects of interferon-\u03b2 in multiple sclerosis patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12967-020-02329-5","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T09:03:39Z","timestamp":1587027819000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Simultaneous quantification of natural and inducible regulatory T-cell subsets during interferon-\u03b2 therapy of multiple sclerosis patients"],"prefix":"10.1186","volume":"18","author":[{"name":"SURROGATE Study Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Chiarini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruggero","family":"Capra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Serana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Bertoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Sottini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Giustini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Scarpazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Rovaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Torri Clerici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simonetta","family":"Galgani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Solaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta Zaffira","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Visconti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Imberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"2329_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-4614-7953-6_2","volume-title":"Multiple sclerosis immunology","author":"BB Gawlik","year":"2013","unstructured":"Gawlik BB, Hafler DA. Regulatory T cells in MS. In: Yamamura T, Gran B, editors. Multiple sclerosis immunology. New York: Springer; 2013. p. 27\u201347."},{"key":"2329_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01578","author":"H Zhao","year":"2017","unstructured":"Zhao H, Liao X, Kang Y. Tregs: where we are and what comes next? Front Immunol. 2017. https:\/\/doi.org\/10.3389\/fimmu.2017.01578.","journal-title":"Front Immunol."},{"key":"2329_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21861-5","author":"M Sambucci","year":"2018","unstructured":"Sambucci M, Gargano F, De Rosa V, De Bardi M, Picozza M, Placido R, et al. FoxP3 isoforms and PD-1 expression by T regulatory cells in multiple sclerosis. Sci Rep. 2018. https:\/\/doi.org\/10.1038\/s41598-018-21861-5.","journal-title":"Sci Rep."},{"key":"2329_CR4","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s10753-012-9496-8","volume":"35","author":"N Yu","year":"2012","unstructured":"Yu N, Li X, Song W, Li D, Yu D, Zeng X, et al. CD4(+)CD25(+)CD127(low\/-) T cells: a more specific Treg population in human peripheral blood. Inflammation. 2012;35:1773\u201380.","journal-title":"Inflammation."},{"key":"2329_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1084\/jem.20061405","volume":"204","author":"MA Schneider","year":"2007","unstructured":"Schneider MA, Meingassner JG, Lipp M, Moore HD, Rot A. CCR7 is required for the in vivo function of CD4\u2009+\u2009CD25\u2009+\u2009regulatory T cells. J Exp Med. 2007;204:735\u201345.","journal-title":"J Exp Med"},{"key":"2329_CR6","doi-asserted-by":"publisher","first-page":"6467","DOI":"10.4049\/jimmunol.180.10.6467","volume":"180","author":"X Chen","year":"2008","unstructured":"Chen X, Subleski JJ, Kopf H, Howard OM, M\u00e4nnel DN, Oppenheim JJ. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4\u2009+\u2009CD25\u2009+\u2009FoxP3\u2009+\u2009T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol. 2008;180:6467\u201371.","journal-title":"J Immunol."},{"key":"2329_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000092533","volume":"140","author":"M Rahmoun","year":"2006","unstructured":"Rahmoun M, Foussat A, Groux H, P\u00e8ne J, Yssel H, Chanez P. Enhanced frequency of CD18- and CD49b-expressing T cells in peripheral blood of asthmatic patients correlates with disease severity. Int Arch Allergy Immunol. 2006;140:139\u201349.","journal-title":"Int Arch Allergy Immunol"},{"key":"2329_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/nature01315","volume":"421","author":"C Kemper","year":"2003","unstructured":"Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, Atkinson JP. Activation of human CD4+\u2009cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature. 2003;421:388\u201392.","journal-title":"Nature"},{"key":"2329_CR9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jneuroim.2006.09.012","volume":"182","author":"C de Andr\u00e9s","year":"2007","unstructured":"de Andr\u00e9s C, Aristimu\u00f1o C, de Las Heras V, Mart\u00ednez-Gin\u00e9s ML, Bartolom\u00e9 M, Arroyo R, et al. Interferon beta-1a therapy enhances CD4+\u2009regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2007;182:204\u201311.","journal-title":"J Neuroimmunol"},{"key":"2329_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jneuroim.2009.08.007","volume":"215","author":"AA Vandenbark","year":"2009","unstructured":"Vandenbark AA, Huan J, Agotsch M, La Tocha D, Goelz S, Offner H, et al. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+\u2009CD25+\u2009Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol. 2009;215:125\u20138.","journal-title":"J Neuroimmunol"},{"key":"2329_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jneuroim.2009.10.013","volume":"218","author":"A Namdar","year":"2010","unstructured":"Namdar A, Nikbin B, Ghabaee M, Bayati A, Izad M. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. J Neuroimmunol. 2010;218:120\u20134.","journal-title":"J Neuroimmunol"},{"key":"2329_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016287","author":"S Ni Choileain","year":"2011","unstructured":"Ni Choileain S, Weyand NJ, Neumann C, Thomas J, So M, Astier AL. The dynamic processing of CD46 intracellular domains provides a molecular rheostat for T cell activation. PLoS ONE. 2011. https:\/\/doi.org\/10.1371\/journal.pone.0016287.","journal-title":"PLoS ONE"},{"key":"2329_CR13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/eji.200737271","volume":"38","author":"I Martinez-Forero","year":"2008","unstructured":"Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, Inoges S, de Cerio ALD, Palacios R, et al. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol. 2008;38:576\u201386.","journal-title":"Eur J Immunol"},{"key":"2329_CR14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nm.3485","volume":"20","author":"Y Liu","year":"2014","unstructured":"Liu Y, Carlsson R, Comabella M, Wang J, Kosicki M, Carrion B, et al. FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat Med. 2014;20:272\u201382.","journal-title":"Nat Med"},{"key":"2329_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.metabol.2017.08.011","volume":"77","author":"C La Rocca","year":"2017","unstructured":"La Rocca C, Carbone F, De Rosa V, Colamatteo A, Galgani M, Perna F, et al. Immunometabolic profiling of T cells from patients with relapsing-remitting multiple sclerosis reveals an impairment in glycolysis and mitochondrial respiration. Metabolism. 2017;77:39\u201346.","journal-title":"Metabolism."},{"key":"2329_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jneuroim.2007.06.006","volume":"189","author":"R Capra","year":"2007","unstructured":"Capra R, Sottini A, Cordioli C, Serana F, Chiarini M, Caimi L, et al. IFNbeta bioavailability in multiple sclerosis patients: MxA versus antibody-detecting assays. J Neuroimmunol. 2007;189:102\u201310.","journal-title":"J Neuroimmunol"},{"key":"2329_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292\u2013302.","journal-title":"Ann Neurol"},{"key":"2329_CR18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP, STROBE Initiative. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453\u20137.","journal-title":"Lancet"},{"key":"2329_CR19","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1177\/1352458511427720","volume":"18","author":"M Chiarini","year":"2012","unstructured":"Chiarini M, Serana F, Zanotti C, Capra R, Rasia S, Rottoli M, et al. Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy. Mult Scler. 2012;18:788\u201398.","journal-title":"Mult Scler."},{"key":"2329_CR20","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1515\/CCLM.2010.263","volume":"48","author":"C Zanotti","year":"2010","unstructured":"Zanotti C, Ghidini C, Lamorgese C, Caimi L, Capra R, Imberti L. Transfer of myxovirus-protein-A mRNA assay for interferon-\u03b2 bioactivity measurement in multiple sclerosis patients to routine laboratory practice. A 4-year experience. Clin Chem Lab Med. 2010;48:1235\u20138.","journal-title":"Clin Chem Lab Med"},{"key":"2329_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/29.9.e45","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001. https:\/\/doi.org\/10.1093\/nar\/29.9.e45.","journal-title":"Nucleic Acids Res"},{"key":"2329_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/cyto.b.21228","volume":"90","author":"M Arroz","year":"2016","unstructured":"Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90:31\u20139.","journal-title":"Cytometry B Clin Cytom."},{"key":"2329_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","volume":"12","author":"A Winkelmann","year":"2016","unstructured":"Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol. 2016;12:217\u201333.","journal-title":"Nat Rev Neurol."},{"key":"2329_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nri.2016.125","volume":"17","author":"P Brodin","year":"2017","unstructured":"Brodin P, Davis MM. Human immune system variation. Nat Rev Immunol. 2017;17:21\u20139.","journal-title":"Nat Rev Immunol"},{"key":"2329_CR25","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/eji.200737201","volume":"37","author":"A Menning","year":"2007","unstructured":"Menning A, H\u00f6pken UE, Siegmund K, Lipp M, Hamann A, Huehn J. Distinctive role of CCR7 in migration and functional activity of naive- and effector\/memory-like Treg subsets. Eur J Immunol. 2007;37:1575\u201383.","journal-title":"Eur J Immunol"},{"key":"2329_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/290878","author":"F Stenard","year":"2014","unstructured":"Stenard F, Morales O, Ghazal K, Viallon V, Aoudjehane L, Ouaguia L, et al. CD49b, a major marker of regulatory T-cells type 1, predicts the response to antiviral therapy of recurrent hepatitis C after liver transplantation. Biomed Res Int. 2014. https:\/\/doi.org\/10.1155\/2014\/290878.","journal-title":"Biomed Res Int"},{"key":"2329_CR27","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1172\/JCI29251","volume":"116","author":"AL Astier","year":"2006","unstructured":"Astier AL, Meiffren G, Freeman S, Hafler DA. Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest. 2006;116:3252\u20137.","journal-title":"J Clin Invest."},{"key":"2329_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02947","author":"M Sambucci","year":"2019","unstructured":"Sambucci M, Gargano F, Guerrera G, Battistini L, Borsellino G. One, no one, and one hundred thousand: T regulatory cells\u2019 multiple identities in neuroimmunity. Front Immunol. 2019. https:\/\/doi.org\/10.3389\/fimmu.2019.02947.","journal-title":"Front Immunol."},{"key":"2329_CR29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nn.4528","volume":"20","author":"Y Dombrowski","year":"2017","unstructured":"Dombrowski Y, O\u2019Hagan T, Dittmer M, Penalva R, Mayoral SR, Bankhead P, et al. Regulatory T cells promote myelin regeneration in the central nervous system. Nat Neurosci. 2017;20:674\u201380.","journal-title":"Nat Neurosci"},{"key":"2329_CR30","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10072-003-0190-3","volume":"24","author":"RM Ruggieri","year":"2003","unstructured":"Ruggieri RM, Settipani N, Viviano L, Attanasio M, Giglia L, Almasio P, et al. Long-term interferon-beta treatment for multiple sclerosis. Neurol Sci. 2003;24:361\u20134.","journal-title":"Neurol Sci."},{"key":"2329_CR31","doi-asserted-by":"publisher","DOI":"10.4081\/ni.2019.8177","author":"E J\u00e4rvinen","year":"2019","unstructured":"J\u00e4rvinen E, Murtonen A, Tervomaa M, Sumelahti ML. Interferon \u03b2-1a subcutaneously 3 times\/week clinical outcome in relapsing multiple sclerosis in Finland. Neurol Int. 2019. https:\/\/doi.org\/10.4081\/ni.2019.8177.","journal-title":"Neurol Int."},{"key":"2329_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1136\/ejhpharm-2017-001286","volume":"26","author":"E Bartolom\u00e9-Garc\u00eda","year":"2019","unstructured":"Bartolom\u00e9-Garc\u00eda E, Usarralde-P\u00e9rez \u00c1, Sanmart\u00edn-Fenollera P, P\u00e9rez-Encinas M. Persistence and adherence to interferon and glatiramer acetate in patients with multiple sclerosis. Eur J Hosp Pharm. 2019;26:23\u20138.","journal-title":"Eur J Hosp Pharm."},{"key":"2329_CR33","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/ni810","volume":"3","author":"JC Marie","year":"2002","unstructured":"Marie JC, Astier AL, Rivailler P, Rabourdin-Combe C, Wild TF, Horvat B. Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. Nat Immunol. 2002;3:659\u201366.","journal-title":"Nat Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02329-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-020-02329-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-020-02329-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T01:27:31Z","timestamp":1618536451000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-020-02329-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2329"],"URL":"https:\/\/doi.org\/10.1186\/s12967-020-02329-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"type":"electronic","value":"1479-5876"}],"subject":[],"published":{"date-parts":[[2020,4,16]]},"assertion":[{"value":"22 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol followed in this study was in agreement with the guidelines of the Declaration of Helsinki and was approved by the Ethical Committee of of Brescia (protocol n. 28961 of June 21, 2012). A written informed consent was signed by all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D Bertoli, M.Z. Conti, S. Galgani, V. Giustini, C. Scarpazza, F. Serana, C. Solaro, and A. Sottini have no competing interests. M. Chiarini has received a fellowship from Merck Serono. R. Capra has received lecture fees and\/or travel grants from Biogen, Celgene, Genzyme-Sanofi, Novartis, and Teva. D. Ferraro has received travel grants and\/or speaker honoraria from Biogen, Genzyme-Sanofi, Merck Serono, Novartis, and Teva and has participated to scientific Advisory Board for Biogen, Novartis, and Roche. L. Imberti has received speaker honoraria from Biogen, Genzyme-Sanofi, Merck Serono, and Novartis and has participated to scientific Advisory Board for Biogen. She has received research funding from FISM (Fondazione Italiana Sclerosi Multipla) and research support from Genzyme-Sanofi and Merck Serono. V. Torri Clerici has participated to scientific Advisory Board for Biogen, Merck Serono, Novartis, and Roche and has received funding for traveling and honoraria for speaking or writing from Almirall, Genzyme-Sanofi, Novartis, Roche, and Teva. She received support for research project by Almirall. A. Visconti is employed of Merck Serono S.p.A., an affiliate of Merck KGaA, Darmstadt, Germany.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}